| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation
|
Hua, Jingsheng
|
|
|
20 |
9 |
p. 610-616
|
article
|
| 2 |
Biologic Implications of t(11;14) in Multiple Myeloma Explained With a Case of Refractory Disease Sensitive to Venetoclax
|
Soleimani, Arshia
|
|
|
20 |
9 |
p. e556-e559
|
article
|
| 3 |
Catastrophic Antiphospholipid Syndrome as the Initial Presentation of Waldenstrom Macroglobulinemia
|
Kim, Dong
|
|
|
20 |
9 |
p. e547-e550
|
article
|
| 4 |
Comparison of Overall Survival Between De Novo and Secondary Acute Lymphoblastic Leukemia Patients of Different Ages
|
Zhong, Jiansheng
|
|
|
20 |
9 |
p. e622-e627
|
article
|
| 5 |
Editorial Board
|
|
|
|
20 |
9 |
p. A4-A5
|
article
|
| 6 |
Evolving Role of Daratumumab: From Backbencher to Frontline Agent
|
Jain, Ankur
|
|
|
20 |
9 |
p. 572-587
|
article
|
| 7 |
High-Scatter Lymphocytes in the Blood of Erythrodermic Cutaneous T-Cell Lymphoma: Evidence for Large-Cell Transformation?
|
Vonderheid, Eric C.
|
|
|
20 |
9 |
p. 624-631.e2
|
article
|
| 8 |
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities
|
Sallman, David A.
|
|
|
20 |
9 |
p. e597-e605
|
article
|
| 9 |
Impact of Adding Antithymocyte Globulin to Posttransplantation Cyclophosphamide in Haploidentical Stem-Cell Transplantation
|
El-Cheikh, Jean
|
|
|
20 |
9 |
p. 617-623
|
article
|
| 10 |
Impact of an Oncology Clinical Pharmacist Specialist in an Outpatient Multiple Myeloma Clinic
|
Virani, Amin
|
|
|
20 |
9 |
p. e543-e546
|
article
|
| 11 |
Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients
|
Al Saleh, Abdullah S.
|
|
|
20 |
9 |
p. 596-601
|
article
|
| 12 |
KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation
|
Cowan, Andrew J.
|
|
|
20 |
9 |
p. 602-609
|
article
|
| 13 |
Management of Adverse Events From the Combination of Rituximab and Lenalidomide in the Treatment of Patients With Follicular and Low-Grade Non-Hodgkin Lymphoma
|
Cheson, Bruce D.
|
|
|
20 |
9 |
p. 563-571
|
article
|
| 14 |
Myeloma CAR-T CRS Management With IL-1R Antagonist Anakinra
|
Jatiani, Shashidhar S.
|
|
|
20 |
9 |
p. 632-636.e1
|
article
|
| 15 |
No Differences in Outcomes Between JAK2 V617F–Positive Patients with Variant Allele Fraction < 2% Versus 2-10%: A 6-Year Province-wide Retrospective Analysis
|
Limvorapitak, Wasithep
|
|
|
20 |
9 |
p. e569-e578
|
article
|
| 16 |
Outcome of CD20-positive Adult B-cell Acute Lymphoblastic Leukemia and the Impact of Rituximab Therapy
|
Alduailej, Hanan
|
|
|
20 |
9 |
p. e560-e568
|
article
|
| 17 |
Primary Plasma Cell Neoplasm of the Kidney Without Formation of a Mass and Its Renal Manifestations: An Interstitial Variant of Renal Plasmacytoma?
|
Wyeth, Autumn
|
|
|
20 |
9 |
p. e551-e555
|
article
|
| 18 |
Prognostic Significance of Absolute Lymphocyte Count, Absolute Monocyte Count, and Absolute Lymphocyte Count to Absolute Monocyte Count Ratio in Follicular Non-Hodgkin Lymphoma
|
Mohsen, Asmaa
|
|
|
20 |
9 |
p. e606-e615
|
article
|
| 19 |
Prognostic Value of Baseline Serum Lactate Dehydrogenase Level in Patients With Hairy Cell Leukemia
|
Maral, Senem
|
|
|
20 |
9 |
p. e616-e621
|
article
|
| 20 |
Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma
|
Al Hadidi, Samer
|
|
|
20 |
9 |
p. e579-e589
|
article
|
| 21 |
Splenectomy in Myelofibrosis: Indications, Efficacy, and Complications
|
Malato, Alessandra
|
|
|
20 |
9 |
p. 588-595
|
article
|
| 22 |
Table of Contents
|
|
|
|
20 |
9 |
p. A6-A9
|
article
|
| 23 |
The Use of 20% Subcutaneous Immunoglobulin Replacement Therapy in Patients With B Cell Non-Hodgkin Lymphoma With Humoral Immune Dysfunction After Treatment With Rituximab
|
Mustafa, S. Shahzad
|
|
|
20 |
9 |
p. e590-e596
|
article
|
Journal description